- Home
- ETON vs CADL Comparison
ETON vs CADL Comparison
Compare ETON & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- CADL
- Stock Information
- Founded
- ETON 2017
- CADL 1999
- Country
- ETON United States
- CADL United States
- Employees
- ETON N/A
- CADL N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- ETON Health Care
- CADL Health Care
- Exchange
- ETON Nasdaq
- CADL Nasdaq
- Market Cap
- ETON 329.8M
- CADL 306.4M
- IPO Year
- ETON 2018
- CADL 2021
- Fundamental
- Price
- ETON $14.42
- CADL $8.38
- Analyst Decision
- ETON Strong Buy
- CADL Strong Buy
- Analyst Count
- ETON 3
- CADL 4
- Target Price
- ETON $27.67
- CADL $21.00
- AVG Volume (30 Days)
- ETON 248.9K
- CADL 1.2M
- Earning Date
- ETON 03-18-2025
- CADL 03-13-2025
- Dividend Yield
- ETON N/A
- CADL N/A
- EPS Growth
- ETON N/A
- CADL N/A
- EPS
- ETON N/A
- CADL N/A
- Revenue
- ETON $39,011,000.00
- CADL N/A
- Revenue This Year
- ETON $107.69
- CADL N/A
- Revenue Next Year
- ETON $65.50
- CADL N/A
- P/E Ratio
- ETON N/A
- CADL N/A
- Revenue Growth
- ETON 23.29
- CADL N/A
- 52 Week Low
- ETON $3.03
- CADL $1.40
- 52 Week High
- ETON $18.41
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- ETON 45.14
- CADL 48.83
- Support Level
- ETON $12.73
- CADL $8.13
- Resistance Level
- ETON $15.73
- CADL $9.08
- Average True Range (ATR)
- ETON 0.91
- CADL 0.57
- MACD
- ETON 0.00
- CADL -0.02
- Stochastic Oscillator
- ETON 56.17
- CADL 60.67
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.